FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015747658> ?p ?o ?g. }

• W2015747658 endingPage "188" @default.
• W2015747658 startingPage "180" @default.
• W2015747658 abstract "To determine if obese non-insulin-dependent diabetic patients lose more weight when treated for 24 weeks (6 months) with orlistat (120 mg t.i.d.), in conjunction with a hypocaloric diet plus behavioural counselling, than when treated by placebo (t.i.d.) plus similar instructions. The secondary objectives were to evaluate the effects on glucose profile and to determine the tolerability and safety of orlistat.Double-blind, parallel, randomized, placebo-controlled, multicentre study.Obese, non-insulin-dependent diabetic patients, aged 18-70 years old, with BMI > 27 kg/m2, evaluated at 10 Latin-American centres, in five countries. EFFICACY AND TOLERABILITY MEASUREMENTS: After screened, eligible patients passed by a 2-week placebo run-in period receiving a hypocaloric diet. On day 0, patients were randomized to orlistat or placebo for 24 weeks. At each visit, body weight, blood pressure and waist circumference were measured. At the screening visit, baseline visit (week 0), and at weeks 8, 16 and 24, a central laboratory was in charge of measuring fasting glucose and insulin, HbA1c, postprandial glucose and insulin, fasting total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and postprandial triglycerides. Other safety laboratory assessments were measured locally at the screening visit, baseline visit and at the end of the study. Adverse events were assessed at each visit from baseline.After 24 weeks of treatment, the orlistat group lost an average of 4.7% of initial body weight vs. 3.0% in the placebo group (p = 0.0003). A greater weight loss was achieved in the orlistat compared with the placebo group (4.24 +/- 0.23 vs. 2.58 +/- 1.46 kg, p = 0.0003). Almost twice as many patients receiving orlistat (30% vs. 17%) lost > or = 5% of initial body weight (p = 0.003). Orlistat treatment plus diet compared to placebo plus diet was associated with significant improvement in glycaemic control, as reflected in decreases in HbA1c (p = 0.04), fasting plasma glucose (p = 0.036) and postprandial glucose (p = 0.05). Orlistat-treated patients had a mean decrease in glucose levels of 1.00 +/- 0.34 mmol/l [3.7%] vs. 0.01 +/- 0.30 mmol/l for placebo group, at week 24 and an absolute decrease of HbA1c of 0.61 +/- 0.15 vs. a decrease of 0.22 +/- 0.14% in the placebo group. Orlistat therapy also resulted in significantly greater improvements than placebo in lipid profile, with reductions in total cholesterol (p = 0.0001) and LDL-cholesterol (p = 0.002). Mild to moderate transient gastrointestinal events were reported, mainly with orlistat treatment, but their association with withdrawal from the study was low.Orlistat is a useful and an effective therapy in obese diabetic patients, promoting clinically significant weight loss and improved glycaemic control and lipid profile." @default.
• W2015747658 created "2016-06-24" @default.
• W2015747658 creator A5003809978 @default.
• W2015747658 creator A5013052910 @default.
• W2015747658 creator A5014511991 @default.
• W2015747658 creator A5016274784 @default.
• W2015747658 creator A5020099208 @default.
• W2015747658 creator A5045341413 @default.
• W2015747658 creator A5052849026 @default.
• W2015747658 creator A5059993395 @default.
• W2015747658 creator A5072131881 @default.
• W2015747658 creator A5086288331 @default.
• W2015747658 creator A5088978548 @default.
• W2015747658 date "2003-04-04" @default.
• W2015747658 modified "2023-10-17" @default.
• W2015747658 title "Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients" @default.
• W2015747658 cites W1684647427 @default.
• W2015747658 cites W1946491572 @default.
• W2015747658 cites W1964227153 @default.
• W2015747658 cites W1970980232 @default.
• W2015747658 cites W1977996473 @default.
• W2015747658 cites W1987922225 @default.
• W2015747658 cites W2003301702 @default.
• W2015747658 cites W2011296644 @default.
• W2015747658 cites W2030142553 @default.
• W2015747658 cites W2044964910 @default.
• W2015747658 cites W2046799957 @default.
• W2015747658 cites W2048083913 @default.
• W2015747658 cites W2049929759 @default.
• W2015747658 cites W2056910132 @default.
• W2015747658 cites W2082695535 @default.
• W2015747658 cites W2100145655 @default.
• W2015747658 cites W2120134933 @default.
• W2015747658 cites W2122944518 @default.
• W2015747658 cites W2132930967 @default.
• W2015747658 cites W2134860420 @default.
• W2015747658 cites W2136520528 @default.
• W2015747658 cites W2150616092 @default.
• W2015747658 cites W2156782959 @default.
• W2015747658 cites W2334309509 @default.
• W2015747658 cites W2337133379 @default.
• W2015747658 cites W4240552830 @default.
• W2015747658 cites W4250413101 @default.
• W2015747658 doi "https://doi.org/10.1046/j.1463-1326.2003.00262.x" @default.
• W2015747658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12681025" @default.
• W2015747658 hasPublicationYear "2003" @default.
• W2015747658 type Work @default.
• W2015747658 sameAs 2015747658 @default.
• W2015747658 citedByCount "62" @default.
• W2015747658 countsByYear W20157476582012 @default.
• W2015747658 countsByYear W20157476582013 @default.
• W2015747658 countsByYear W20157476582015 @default.
• W2015747658 countsByYear W20157476582016 @default.
• W2015747658 countsByYear W20157476582017 @default.
• W2015747658 countsByYear W20157476582019 @default.
• W2015747658 countsByYear W20157476582021 @default.
• W2015747658 countsByYear W20157476582022 @default.
• W2015747658 countsByYear W20157476582023 @default.
• W2015747658 crossrefType "journal-article" @default.
• W2015747658 hasAuthorship W2015747658A5003809978 @default.
• W2015747658 hasAuthorship W2015747658A5013052910 @default.
• W2015747658 hasAuthorship W2015747658A5014511991 @default.
• W2015747658 hasAuthorship W2015747658A5016274784 @default.
• W2015747658 hasAuthorship W2015747658A5020099208 @default.
• W2015747658 hasAuthorship W2015747658A5045341413 @default.
• W2015747658 hasAuthorship W2015747658A5052849026 @default.
• W2015747658 hasAuthorship W2015747658A5059993395 @default.
• W2015747658 hasAuthorship W2015747658A5072131881 @default.
• W2015747658 hasAuthorship W2015747658A5086288331 @default.
• W2015747658 hasAuthorship W2015747658A5088978548 @default.
• W2015747658 hasConcept C126322002 @default.
• W2015747658 hasConcept C134018914 @default.
• W2015747658 hasConcept C142724271 @default.
• W2015747658 hasConcept C197934379 @default.
• W2015747658 hasConcept C204787440 @default.
• W2015747658 hasConcept C27081682 @default.
• W2015747658 hasConcept C2778163477 @default.
• W2015747658 hasConcept C2778199505 @default.
• W2015747658 hasConcept C2778270857 @default.
• W2015747658 hasConcept C2778375690 @default.
• W2015747658 hasConcept C2779306644 @default.
• W2015747658 hasConcept C2780780548 @default.
• W2015747658 hasConcept C511355011 @default.
• W2015747658 hasConcept C544821477 @default.
• W2015747658 hasConcept C71924100 @default.
• W2015747658 hasConcept C90924648 @default.
• W2015747658 hasConceptScore W2015747658C126322002 @default.
• W2015747658 hasConceptScore W2015747658C134018914 @default.
• W2015747658 hasConceptScore W2015747658C142724271 @default.
• W2015747658 hasConceptScore W2015747658C197934379 @default.
• W2015747658 hasConceptScore W2015747658C204787440 @default.
• W2015747658 hasConceptScore W2015747658C27081682 @default.
• W2015747658 hasConceptScore W2015747658C2778163477 @default.
• W2015747658 hasConceptScore W2015747658C2778199505 @default.
• W2015747658 hasConceptScore W2015747658C2778270857 @default.
• W2015747658 hasConceptScore W2015747658C2778375690 @default.
• W2015747658 hasConceptScore W2015747658C2779306644 @default.
• W2015747658 hasConceptScore W2015747658C2780780548 @default.

• next